{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:47:45Z","timestamp":1791380865035,"version":"4.3.3"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T00:00:00Z","timestamp":1506988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/leu.2017.303","type":"journal-article","created":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T09:18:11Z","timestamp":1507022291000},"page":"931-940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"32","author":[{"given":"I S","family":"Jerchel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Q","family":"Hoogkamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I M","family":"Ari\u00ebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E M P","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N J M","family":"Besselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Boeree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H A","family":"de Groot-Kruseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"de Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Horstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Escherich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Cuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Koudijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M L","family":"den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,3]]},"reference":[{"key":"BFleu2017303_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11684-015-0381-3","volume":"9","author":"CH Pui","year":"2015","unstructured":"Pui CH . Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia. Front Med 2015; 9: 1\u20139.","journal-title":"Front Med"},{"key":"BFleu2017303_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","volume":"50","author":"CH Pui","year":"2013","unstructured":"Pui CH, Evans WE . A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol 2013; 50: 185\u2013196.","journal-title":"Semin Hematol"},{"key":"BFleu2017303_CR3","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/leu.2013.44","volume":"27","author":"GM Marshall","year":"2013","unstructured":"Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia 2013; 27: 1497\u20131503.","journal-title":"Leukemia"},{"key":"BFleu2017303_CR4","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","volume":"34","author":"R Pieters","year":"2016","unstructured":"Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol 2016; 34: 2591\u20132601.","journal-title":"J Clin Oncol"},{"key":"BFleu2017303_CR5","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood.V86.10.3861.bloodjournal86103861","volume":"86","author":"E Klumper","year":"1995","unstructured":"Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hahlen K et al. In vitro cellular drug resistance in children with relapsed\/refractory acute lymphoblastic leukemia. Blood 1995; 86: 3861\u20133868.","journal-title":"Blood"},{"key":"BFleu2017303_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fonc.2014.00160","volume":"4","author":"T Knight","year":"2014","unstructured":"Knight T, Irving JA . Ras\/Raf\/MEK\/ERK pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting. Front Oncol 2014; 4: 160.","journal-title":"Front Oncol"},{"key":"BFleu2017303_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761\u2013774.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2017303_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/520278a","volume":"520","author":"H Ledford","year":"2015","unstructured":"Ledford H . Cancer: the Ras renaissance. Nature 2015; 520: 278\u2013280.","journal-title":"Nature"},{"key":"BFleu2017303_CR9","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior IA, Lewis PD, Mattos C . A comprehensive survey of Ras mutations in cancer. Cancer Res 2012; 72: 2457\u20132467.","journal-title":"Cancer Res"},{"key":"BFleu2017303_CR10","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","volume":"124","author":"MR Burgess","year":"2014","unstructured":"Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J et al. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood 2014; 124: 3947\u20133955.","journal-title":"Blood"},{"key":"BFleu2017303_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc4000","volume":"15","author":"CJ Caunt","year":"2015","unstructured":"Caunt CJ, Sale MJ, Smith PD, Cook SJ . MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer 2015; 15: 577\u2013592.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2017303_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature12441","volume":"501","author":"G Hatzivassiliou","year":"2013","unstructured":"Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 2013; 501: 232\u2013236.","journal-title":"Nature"},{"key":"BFleu2017303_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.14694\/EdBook_AM.2015.35.177","volume":"35","author":"R Sullivan","year":"2015","unstructured":"Sullivan R, LoRusso P, Boerner S, Dummer R . Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book 2015; 35: 177\u2013186.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"BFleu2017303_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30\u201339.","journal-title":"N Engl J Med"},{"key":"BFleu2017303_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","volume":"14","author":"J Farley","year":"2013","unstructured":"Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 2013; 14: 134\u2013140.","journal-title":"Lancet Oncol"},{"key":"BFleu2017303_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013; 368: 623\u2013632.","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"BFleu2017303_CR17","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.1200\/jco.2011.29.15_suppl.6506","volume":"29","author":"G. Borthakur","year":"2011","unstructured":"Borthakur G, Popplewell L, Kirschbaum MH, Foran JM, Kadia TM, Jabbour E et al. Phase I\/II trial of the MEK1\/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed\/refractory myeloid malignancies: evidence of activity in pts with RAS mutation. J Clin Oncol 2011; 29: (abstract 6506). http:\/\/meetinglibrary.asco.org\/record\/61066\/abstract .","journal-title":"Journal of Clinical Oncology"},{"key":"BFleu2017303_CR18","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J et al.Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877\u20131888.","journal-title":"N Engl J Med"},{"key":"BFleu2017303_CR19","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/blood-2012-05-378596","volume":"120","author":"AF Ward","year":"2012","unstructured":"Ward AF, Braun BS, Shannon KM . Targeting oncogenic Ras signaling in hematologic malignancies. Blood 2012; 120: 3397\u20133406.","journal-title":"Blood"},{"key":"BFleu2017303_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/sj.leu.2403272","volume":"18","author":"JP Perentesis","year":"2004","unstructured":"Perentesis JP, Bhatia S, Boyle E, Shao Y, Shu XO, Steinbuch M et al. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia 2004; 18: 685\u2013692.","journal-title":"Leukemia"},{"key":"BFleu2017303_CR21","doi-asserted-by":"publisher","first-page":"9268","DOI":"10.1073\/pnas.85.23.9268","volume":"85","author":"A Neri","year":"1988","unstructured":"Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R . Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA 1988; 85: 9268\u20139272.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017303_CR22","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1182\/blood-2011-03-341412","volume":"118","author":"J Zhang","year":"2011","unstructured":"Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011; 118: 3080\u20133087.","journal-title":"Blood"},{"key":"BFleu2017303_CR23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/ng.3301","volume":"47","author":"K Paulsson","year":"2015","unstructured":"Paulsson K, Lilljebjorn H, Biloglav A, Olsson L, Rissler M, Castor A et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet 2015; 47: 672\u2013676.","journal-title":"Nat Genet"},{"key":"BFleu2017303_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/ng.2532","volume":"45","author":"L Holmfeldt","year":"2013","unstructured":"Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45: 242\u2013252.","journal-title":"Nat Genet"},{"key":"BFleu2017303_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ng.3230","volume":"47","author":"AK Andersson","year":"2015","unstructured":"Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet 2015; 47: 330\u2013337.","journal-title":"Nat Genet"},{"key":"BFleu2017303_CR26","doi-asserted-by":"publisher","first-page":"6604","DOI":"10.1038\/ncomms7604","volume":"6","author":"X Ma","year":"2015","unstructured":"Ma X, Edmonson M, Yergeau D, Muzny DM, Hampton OA, Rusch M et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun 2015; 6: 6604.","journal-title":"Nat Commun"},{"key":"BFleu2017303_CR27","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","volume":"124","author":"J Irving","year":"2014","unstructured":"Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 2014; 124: 3420\u20133430.","journal-title":"Blood"},{"key":"BFleu2017303_CR28","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1182\/blood-2016-03-704973","volume":"128","author":"JA Irving","year":"2016","unstructured":"Irving JA, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood 2016; 128: 911\u2013922.","journal-title":"Blood"},{"key":"BFleu2017303_CR29","doi-asserted-by":"publisher","first-page":"11306","DOI":"10.1073\/pnas.1608420113","volume":"113","author":"K Oshima","year":"2016","unstructured":"Oshima K, Khiabanian H, da Silva-Almeida AC, Tzoneva G, Abate F, Ambesi-Impiombato A et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2016; 113: 11306\u201311311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017303_CR30","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.3324\/haematol.2014.112995","volume":"100","author":"IM Aries","year":"2015","unstructured":"Aries IM, van den Dungen RE, Koudijs MJ, Cuppen E, Voest E, Molenaar JJ et al. Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance. Haematologica 2015; 100: e132\u2013e136.","journal-title":"Haematologica"},{"key":"BFleu2017303_CR31","doi-asserted-by":"publisher","first-page":"6803","DOI":"10.1158\/0008-5472.CAN-08-0101","volume":"68","author":"M Case","year":"2008","unstructured":"Case M, Matheson E, Minto L, Hassan R, Harrison CJ, Bown N et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res 2008; 68: 6803\u20136809.","journal-title":"Cancer Res"},{"key":"BFleu2017303_CR32","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/leu.2015.107","volume":"29","author":"K Malinowska-Ozdowy","year":"2015","unstructured":"Malinowska-Ozdowy K, Frech C, Schonegger A, Eckert C, Cazzaniga G, Stanulla M et al. KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. Leukemia 2015; 29: 1656\u20131667.","journal-title":"Leukemia"},{"key":"BFleu2017303_CR33","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/JCO.2003.11.031","volume":"21","author":"ML Den Boer","year":"2003","unstructured":"Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 3262\u20133268.","journal-title":"J Clin Oncol"},{"key":"BFleu2017303_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","volume":"10","author":"ML Den Boer","year":"2009","unstructured":"Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10: 125\u2013134.","journal-title":"Lancet Oncol"},{"key":"BFleu2017303_CR35","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","volume":"122","author":"A van der Veer","year":"2013","unstructured":"van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013; 122: 2622\u20132629.","journal-title":"Blood"},{"key":"BFleu2017303_CR36","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V90.7.2723","volume":"90","author":"GJ Kaspers","year":"1997","unstructured":"Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997; 90: 2723\u20132729.","journal-title":"Blood"},{"key":"BFleu2017303_CR37","unstructured":"Li H Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv preprint arXiv: 13033997, 2013.."},{"key":"BFleu2017303_CR38","unstructured":"Garrison E, Marth G Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv: 12073907, 2012."},{"key":"BFleu2017303_CR39","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568\u2013576.","journal-title":"Genome Res"},{"key":"BFleu2017303_CR40","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1093\/bioinformatics\/btr509","volume":"27","author":"H Li","year":"2011","unstructured":"Li H . A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 2011; 27: 2987\u20132993.","journal-title":"Bioinformatics"},{"key":"BFleu2017303_CR41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491\u2013498.","journal-title":"Nat Genet"},{"key":"BFleu2017303_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 2012; 6: 80\u201392.","journal-title":"Fly"},{"key":"BFleu2017303_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/humu.22932","volume":"37","author":"X Liu","year":"2016","unstructured":"Liu X, Wu C, Li C, Boerwinkle E . dbNSFP v3.0: a one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. Hum Mutat 2016; 37: 235\u2013241.","journal-title":"Hum Mutat"},{"issue":"Database issue","key":"BFleu2017303_CR44","first-page":"D800","volume":"43","author":"SA Forbes","year":"2015","unstructured":"Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43 (Database issue): D800\u2013D811.","journal-title":"Nucleic Acids Res"},{"key":"BFleu2017303_CR45","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3324\/haematol.2010.039735","volume":"96","author":"G Escherich","year":"2011","unstructured":"Escherich G, Troger A, Gobel U, Graubner U, Pekrun A, Jorch N et al. The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97). Haematologica 2011; 96: 854\u2013862.","journal-title":"Haematologica"},{"key":"BFleu2017303_CR46","unstructured":"Gray RJ cmprsk: Subdistribution analysis of competing risks. R package version 2.2-7, 2013. http:\/\/CRAN.R-project.org\/package=cmprsk ."},{"key":"BFleu2017303_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v038.i07","volume":"38","author":"LC de Wreede","year":"2011","unstructured":"de Wreede LC, Fiocco M, Putter H . mstate: An R package for the analysis of competing risks and multi-state models. J Stat Softw 2011; 38: 1\u201330.","journal-title":"J Stat Softw"},{"key":"BFleu2017303_CR48","unstructured":"Therneau T A Package for Survival Analysis in S. R Package version 2.38-3, 2012.."},{"key":"BFleu2017303_CR49","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","volume":"25","author":"AG Stephen","year":"2014","unstructured":"Stephen AG, Esposito D, Bagni RK, McCormick F . Dragging ras back in the ring. Cancer Cell 2014; 25: 272\u2013281.","journal-title":"Cancer Cell"},{"key":"BFleu2017303_CR50","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3324\/haematol.2012.067983","volume":"98","author":"EM Driessen","year":"2013","unstructured":"Driessen EM, van Roon EH, Spijkers-Hagelstein JA, Schneider P, de Lorenzo P, Valsecchi MG et al. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. Haematologica 2013; 98: 937\u2013944.","journal-title":"Haematologica"},{"key":"BFleu2017303_CR51","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/ng.3362","volume":"47","author":"U Fischer","year":"2015","unstructured":"Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S, Warnatz HJ et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet 2015; 47: 1020\u20131029.","journal-title":"Nat Genet"},{"key":"BFleu2017303_CR52","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","volume":"18","author":"D Cilloni","year":"2012","unstructured":"Cilloni D, Saglio G . Molecular pathways: BCR-ABL. Clin Cancer Res 2012; 18: 930\u2013937.","journal-title":"Clin Cancer Res"},{"key":"BFleu2017303_CR53","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343\u20133356.","journal-title":"Blood"},{"key":"BFleu2017303_CR54","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ccell.2015.05.008","volume":"28","author":"S Shojaee","year":"2015","unstructured":"Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C et al. Erk negative feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia. Cancer Cell 2015; 28: 114\u2013128.","journal-title":"Cancer Cell"},{"key":"BFleu2017303_CR55","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1084\/jem.181.1.307","volume":"181","author":"CL Sawyers","year":"1995","unstructured":"Sawyers CL, McLaughlin J, Witte ON . Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995; 181: 307\u2013313.","journal-title":"J Exp Med"},{"key":"BFleu2017303_CR56","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1182\/blood.V97.5.1399","volume":"97","author":"A Reichert","year":"2001","unstructured":"Reichert A, Heisterkamp N, Daley GQ, Groffen J . Treatment of Bcr\/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood 2001; 97: 1399\u20131403.","journal-title":"Blood"},{"key":"BFleu2017303_CR57","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.leukres.2015.06.005","volume":"39","author":"C Chen","year":"2015","unstructured":"Chen C, Bartenhagen C, Gombert M, Okpanyi V, Binder V, Rottgers S et al. Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients. Leuk Res 2015; 39: 990\u20131001.","journal-title":"Leuk Res"},{"key":"BFleu2017303_CR58","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/leu.2010.39","volume":"24","author":"J Davidsson","year":"2010","unstructured":"Davidsson J, Paulsson K, Lindgren D, Lilljebjorn H, Chaplin T, Forestier E et al. Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations. Leukemia 2010; 24: 924\u2013931.","journal-title":"Leukemia"},{"key":"BFleu2017303_CR59","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3324\/haematol.2016.153023","volume":"102","author":"B Scheijen","year":"2017","unstructured":"Scheijen B, Boer JM, Marke R, Tijchon E, van Ingen Schenau D, Waanders E et al. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients. Haematologica 2017; 102: 541\u2013551.","journal-title":"Haematologica"},{"key":"BFleu2017303_CR60","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1182\/blood-2015-04-639138","volume":"126","author":"CL Jones","year":"2015","unstructured":"Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K et al. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood 2015; 126: 2202\u20132212.","journal-title":"Blood"},{"key":"BFleu2017303_CR61","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/leu.2009.80","volume":"23","author":"AA Rambal","year":"2009","unstructured":"Rambal AA, Panaguiton ZL, Kramer L, Grant S, Harada H. MEK . inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. Leukemia 2009; 23: 1744\u20131754.","journal-title":"Leukemia"},{"key":"BFleu2017303_CR62","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","volume":"352","author":"JJ van Dongen","year":"1998","unstructured":"van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al.Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731\u20131738.","journal-title":"Lancet"},{"key":"BFleu2017303_CR63","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","volume":"124","author":"J Irving","year":"2014","unstructured":"Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C et al. Ras pathway mutations are highly prevalent in relapsed childhood acute lymphoblastic leukaemia, may act as relapse-drivers and confer sensitivity to MEK inhibition. Blood 2014; 124: 3420\u20133430.","journal-title":"Blood"},{"key":"BFleu2017303_CR64","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/leu.2016.365","volume":"31","author":"C Vesely","year":"2017","unstructured":"Vesely C, Frech C, Eckert C, Cario G, Mecklenbrauker A, Zur Stadt U et al. Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia. Leukemia 2017; 31: 1491\u20131501.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017303","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:10:31Z","timestamp":1684419031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,3]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["BFleu2017303"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.303","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.731684918.793538374","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,3]]},"assertion":[{"value":"5 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}